How to write a case report on a 19-year-old male with Vitamin D dependent rickets type 1, initially mismanaged as nutritional rickets, with a definitive diagnosis via Next-Generation Sequencing (NGS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Writing a Case Report on Vitamin D Dependent Rickets Type 1A with Delayed Diagnosis

Introduction Structure

Your introduction should emphasize that Vitamin D Dependent Rickets Type 1A (VDDR-1A) is a rare autosomal recessive disorder caused by mutations in the CYP27B1 gene, leading to deficiency of 1α-hydroxylase enzyme and impaired conversion of 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D3. 1, 2, 3

Key Points to Include in Introduction:

  • Epidemiology and Genetics: VDDR-1A represents approximately 20% of hypophosphataemic rickets cases (with X-linked hypophosphataemia being the most common at ~80%). 4 The condition is inherited in an autosomal recessive pattern with mutations in CYP27B1 located on chromosome 12q14. 1, 2, 3

  • Clinical Presentation: Typical onset occurs between 2-24 months of age with hypocalcemic rickets, failure to thrive, muscle weakness/hypotonia, seizures from hypocalcemia, and skeletal deformities including bowing of legs, widened wrists and ankles, and rachitic rosary. 1, 2, 3, 5

  • Diagnostic Challenge: The condition is frequently misdiagnosed as nutritional rickets because both present with similar clinical and radiological features. However, VDDR-1A is refractory to standard vitamin D supplementation (cholecalciferol or ergocalciferol) and requires treatment with active vitamin D metabolites (calcitriol or alfacalcidol). 1, 2, 3

  • Biochemical Profile: Characteristic findings include hypocalcemia, hypophosphatemia, elevated alkaline phosphatase, markedly elevated parathyroid hormone (PTH), normal or elevated 25-hydroxyvitamin D, and low or inappropriately normal 1,25-dihydroxyvitamin D3 levels. 2, 3, 5

  • Importance of Early Diagnosis: Delayed diagnosis results in irreversible skeletal deformities, as demonstrated by adult cases where patients develop permanent limb deformities and short stature despite eventual treatment. 6 Early genetic diagnosis in infancy allows prevention of these complications. 6

Discussion Structure

Diagnostic Delay and Mismanagement

The critical teaching point of your case is that VDDR-1A should be suspected when a child with apparent rickets fails to respond to standard vitamin D supplementation, particularly when 25-hydroxyvitamin D levels are normal or elevated. 1, 2, 3

  • Emphasize that nutritional rickets and VDDR-1A can coexist, and diagnosis of VDDR-1A should be considered if serum phosphate levels do not improve after vitamin D supplementation. 4

  • The biochemical hallmark distinguishing VDDR-1A from nutritional rickets is the combination of elevated PTH with normal/high 25-hydroxyvitamin D but low 1,25-dihydroxyvitamin D3. 2, 3, 5

  • Note that approximately 40% of infants and toddlers aged 8-24 months have vitamin D insufficiency, making nutritional rickets common and potentially masking the diagnosis of genetic forms. 4

Role of Next-Generation Sequencing

NGS has revolutionized the diagnosis of rare genetic disorders like VDDR-1A by enabling identification of novel mutations and providing definitive diagnosis when clinical and biochemical findings are suggestive but not conclusive. 2, 3, 6

  • Discuss how molecular genetic analysis should be performed whenever possible before treatment to confirm diagnosis, particularly in cases with negative family history or atypical presentations. 4

  • Extended molecular genetic analysis is helpful to establish diagnosis in unclear cases of hypophosphataemic rickets and can differentiate between various genetic causes including VDDR-1A, VDDR-1B, VDDR-2A, hereditary hypophosphataemic rickets with hypercalciuria (HHRH), and X-linked hypophosphataemia. 4, 6

  • Emphasize that novel mutations continue to be identified, expanding our understanding of CYP27B1 gene mutations. 2, 3, 6, 5

Consequences of Delayed Diagnosis

Your 19-year-old patient represents a critical example of how delayed diagnosis leads to irreversible skeletal deformities that persist into adulthood despite eventual appropriate treatment. 6

  • Adult cases diagnosed late develop permanent limb deformities, disproportionate short stature, and may have complications including nephrocalcinosis from prolonged secondary hyperparathyroidism. 3, 6

  • Radiographic features in your patient likely include severe leg bowing (genu varum or valgus), metaphyseal irregularities, thickened cortical bone, and possibly pseudofractures or early osteoarthritis. 4

  • Unlike nutritional rickets where fractures occur in mobile children aged 8-19 months and are typically long bone or rib fractures, VDDR-1A can present with more severe skeletal involvement including multiple fractures and severe hypotonia. 4, 5

Treatment Principles

Once diagnosed, VDDR-1A requires lifelong treatment with active vitamin D metabolites (calcitriol 0.25-2 µg/day or alfacalcidol) plus calcium supplementation (250-500 mg elemental calcium daily). 7, 1, 2, 3, 6

  • Standard vitamin D2 (ergocalciferol) or D3 (cholecalciferol) supplementation is ineffective because the enzymatic defect prevents conversion to active metabolite. 1, 2, 3

  • Treatment goals include normalization of serum calcium, phosphorus, alkaline phosphatase, and PTH levels, typically achieved within 2-3 months of initiating therapy. 2, 3, 6, 5

  • Monitoring should include periodic measurement of serum calcium, phosphorus, alkaline phosphatase, PTH, and urinary calcium to avoid hypercalcemia and hypercalciuria. 7, 3

  • In your adult patient, treatment will normalize biochemical parameters and may improve bone pain, but skeletal deformities established during growth are irreversible. 6

Differential Diagnosis Considerations

The differential diagnosis of hypophosphataemic rickets includes multiple genetic and acquired conditions that must be distinguished from VDDR-1A. 4

  • X-linked hypophosphataemia (XLH) is the most common inherited cause (~80% of cases), characterized by elevated FGF23, renal phosphate wasting, hypophosphatemia, but normal calcium and inappropriately normal or low 1,25-dihydroxyvitamin D3. 4

  • Hereditary hypophosphataemic rickets with hypercalciuria (HHRH) presents with hypercalciuria before treatment, distinguishing it from VDDR-1A where urinary calcium is typically low. 4

  • Renal Fanconi syndrome causes generalized proximal tubular dysfunction with glucosuria, aminoaciduria, and low molecular mass proteinuria in addition to phosphate wasting. 4, 5

  • Tumor-induced osteomalacia typically presents after the second year of life with symptoms developing later than typical VDDR-1A. 4

Clinical Implications and Recommendations

Early genetic screening should be performed in all children presenting with rickets who have elevated PTH, normal or high 25-hydroxyvitamin D, and low 1,25-dihydroxyvitamin D3, or who fail to respond to standard vitamin D supplementation. 6

  • Consanguinity increases risk for autosomal recessive conditions like VDDR-1A and should prompt earlier genetic evaluation. 3

  • Family screening is essential once an index case is identified, as siblings have 25% risk of being affected. 3

  • Genetic counseling should be provided to families regarding recurrence risk and inheritance patterns. 4

  • In resource-limited settings where genetic testing may not be readily available, empirical trial of calcitriol with close biochemical monitoring can be diagnostic and therapeutic. 1, 2

Unique Aspects of Your Case

  • Highlight the 16-year delay from symptom onset (age 3) to definitive diagnosis (age 19), representing an extreme example of diagnostic delay. 6

  • Discuss how empirical management as "resistant rickets" likely involved higher doses of standard vitamin D without addressing the underlying enzymatic defect. 1, 2

  • Emphasize that NGS provided definitive diagnosis when clinical suspicion alone was insufficient, enabling appropriate targeted therapy. 2, 3, 6

  • Note any specific novel mutations identified in your patient and their predicted functional consequences on 1α-hydroxylase activity. 2, 3, 6, 5

References

Research

[Long term follow up of a patient with type I vitamin D-dependent rickets].

Boletin medico del Hospital Infantil de Mexico, 2015

Research

A Case of Vitamin D-Dependent Rickets Type 1A with a Novel Mutation in the Uzbek Population.

Journal of clinical research in pediatric endocrinology, 2016

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment for Vitamin D Deficiency in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.